Characterization of the role of major histocompatibility complex in type 1 diabetes recurrence after islet transplantation

Transplantation

Volumn 78, Issue 4, 2004, Pages 509-515

  Young, Holly Y ^a   Zucker, Peter ^b   Flavell, Richard A ^c   Jevnikar, Anthony M ^a,b   Singh, Bhagirath ^a,b,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

Author keywords

Cytokines; Cytotoxic lymphocyte; Islet transplantation; MHC class I; MHC class II; Type 1 diabetes

Indexed keywords

BETA 2 MICROGLOBULIN; CYTOKINE; GAMMA INTERFERON; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; CELL DESTRUCTION; CELL INFILTRATION; CLASS II TRANSACTIVATOR GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; EFFECTOR CELL; GENE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HELPER CELL; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; ISOGRAFT; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL;

ANIMALS; BETA 2-MICROGLOBULIN; CYTOKINES; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; ISLETS OF LANGERHANS TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED NOD; NUCLEAR PROTEINS; RECURRENCE; TH1 CELLS; TH2 CELLS; TRANS-ACTIVATORS;

EID: 4143102600     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000128907.83111.C6     Document Type: Article

References (31)

1. Wicker LS. Major histocompatibility complex-linked control of autoimmunity. J Exp Med 1997; 186: 973.
2. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85: 291.
3. Reich EP, von Grafenstein H, Barlow A, et al. Self peptides isolated from MHC glycoproteins of non-obese diabetic mice. J Immunol 1994; 152: 2279.
4. Serreze DV, Leiter EH. Genetic and pathogenic basis of autoimmune diabetes in NOD mice. Curr Opin Immunol 1994; 6: 900.
5. Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol 1993; 23: 3358.
6. Serreze DV, Chapman HD, Varnum DS, et al. Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J Immunol 1997; 158: 3978.
7. Prange S, Zucker P, Jevnikar AM, et al. Transplanted MHC class I-deficient nonobese diabetic mouse islets are protected from autoimmune injury in diabetic nonobese recipients. Transplantation 2001; 71: 982.
8. Guo Z, Wu T, Kirchhof N, et al. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Transplantation 2001; 71: 1656.
9. Makhlouf L, Kishimoto K, Smith, RN et al. The role of autoimmunity in islet aflograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 2002; 51: 3202.
10. Jevnikar AM, Prange S, Zucker P, et al. Role of donor MHC class III genes in the destruction of transplanted islets in NOD mice. Ann N Y Acad Sci 2002; 958: 175.
11. Nagata M, Santamaria P, Kawamura T, et al. Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J Immunol 1994; 152: 2042.
12. Steimle V, Otten LA, Zufferey M, et al. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135.
13. Steimle V, Siegrist CA, Mottet A, et al. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265: 106.
14. Chang CH, Fontes JD, Peterlin M, et al. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med 1994; 180: 1367.
15. Williams GS, Malin M, Vremec D, et al. Mice lacking the transcription factor CIITA-a second look. Int Immunol 1998; 10: 1957.
16. Chang CH, Guerder S, Hong SC, et al. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 1996; 4: 167.
17. Mora C, Wong FS, Chang CH, Flavell RA. Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice. J Immunol 1999; 162: 4576.
18. Kuttler B, Hartmann A, Wanka H. Long-term culture of islets abrogates cytokine-induced or lymphocyte-induced increase of antigen expression on beta cells. Transplantation. 2002; 74(4): 440.
19. McInerney MF, Rath S, Janeway CA Jr. Exclusive expression of MHC class II proteins on CD45+ cells in pancreatic islets of NOD mice. Diabetes 1991; 40(5): 648.
20. Walter U, Toepfer T, Dittmar KE, et al. Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia 2003; 46(8): 1106.
21. Anderson CC, Mukherjee R, Sinclair NR, et al. Hypogammaglobulinemia occurs in Fas-deficient MRL-lpr mice following deletion of MHC class II molecules. Clin Exp Immunol 1997; 109: 473.
22. Grusby MJ, Auchincloss H, Lee R, et al. Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A 1993; 90: 3913.
23. Lieberman SM, Evans AM, Han B, et al. Identification of the B cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A 2003; 100: 8384.
24. Rabinovitch A, Sorensen O, Suarez-Pinzon WL, et al. Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival. Diabetologia 1994; 37: 833.
25. Wang T, Singh B, Warnock GL, et al. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 1992; 41: 114.
26. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998; 14: 129.
27. Nitta Y, Tashiro F, Tokui M, et al. Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Hum Gene Ther 1998; 9: 1701.
28. Moritani M, Yoshimoto K, Tashiro F, et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 1994; 6: 1927.
29. Wogensen L, Lee MS, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice. J Exp Med 1994; 179: 1379.
30. Smith DK, Korbutt GS, Suarez-Pinzon WL, et al. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice. Transplantation 1997; 64: 1040.
31. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, et al. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice. Analysis of cytokine mRNA expression in the graft. Transplantation 1995; 60: 368.